Physician profile

Robert C Sharpe

Orthopaedic Surgery · Merriam, KS

NPI 1093781916

$1,045.16

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$260.77

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Titan Surgical Group, LLC $610.00 2020
Ferring Pharmaceuticals INC. $124.54 2019-2024 Euflexxa
Sanofi-Aventis U.S. LLC $92.91 2019-2023
Depuy Synthes Sales INC. $72.11 2021-2024 Inhance
Stryker Corporation $57.90 2024 Champion, Iconix
Sunovion Pharmaceuticals INC. $30.42 2020
Davol INC. $21.19 2024 Arista Ah Flexitip
Bioventus LLC $19.02 2023 Durolane
Zimmer Biomet Holdings, INC. $17.07 2023 Tapestry

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert C Sharpe

$1,045.16

in general payments reported 2019-2025

Years
2019-2024
Top company
Titan Surgical Group, LLC

https://glasscript.com/doctor/186277/robert-c-sharpe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.